Lysodren
LYSODREN- mitotane tablet
HRA Pharma Rare Diseases
WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK, SEVERE TRAUMA OR INFECTION
Patients treated with LYSODREN are at increased risk for developing adrenal crisis in the setting of shock, severe trauma or infection that may lead to death.
If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. Monitor patients closely for infections and instruct patients to contact their physician immediately if injury, infection, or any other concomitant illness occurs [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)].
1 INDICATIONS AND USAGE
LYSODREN is indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenocortical carcinoma (ACC).
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Evaluation and Testing Before Initiating LYSODREN
Before initiating LYSODREN, evaluate pelvic ultrasound in premenopausal women, liver functions tests and complete blood count [see Warnings and Precautions (5.3, 5.4, 5.5)].
2.2 General Precautions
LYSODREN is a hazardous drug. Advise caregivers to wear disposable gloves when handling LYSODREN tablets [see References (15) and Storage and Handling (16)].
2.3 Recommended Dosage and Administration
Recommended Dosage
- The recommended initial dose of LYSODREN is 2000 mg to 6000 mg orally, in three or four divided doses per day.
- Monitor mitotane plasma levels and increase the dose based on patient tolerance and clinical response incrementally to achieve a mitotane plasma level of 14 to 20 mg/L, or as tolerated. Consider monitoring mitotane plasma levels every 2 weeks after starting treatment and after each dose adjustment.
- The target plasma level is usually reached within a period of 3 to 5 months.
- Monitor mitotane plasma levels periodically (e.g., monthly). Severe neurotoxicity may occur with levels > 20 mg/L.
Dose Adjustments, Monitoring and Discontinuation
- In case of mitotane plasma levels above 20 mg/L without toxicities, consider reducing the dose by 50 to 75%.
- Monitor mitotane plasma levels regularly (e.g., every two months) after discontinuation of treatment. Due to the prolonged half-life, significant levels may persist for weeks after cessation of therapy.
- LYSODREN is lipophilic and accumulates in adipose tissue. Despite maintaining a constant dose, mitotane levels may suddenly increase. Monitor mitotane plasma levels even when LYSODREN has been withheld as adipose tissue may continue to release mitotane [see Clinical Pharmacology (12.3)]. Due to adipose tissue accumulation of mitotane, close monitoring of mitotane plasma levels is recommended in overweight patients and patients with recent weight loss.
Administration
- Swallow LYSODREN tablets whole; do not crush, chew or split.
- Take LYSODREN with food. Timing of the dose relative to meals must be consistent. Administration with high fat food enhances absorption [See Clinical Pharmacology Section (12.3)].
- Do not take tablets showing signs of deterioration.
- Caregivers should wear disposable gloves when handling the tablets. Avoid exposure to crushed and/or broken tablets. If contact with crushed/broken tablets occurs, wash the contaminated skin immediately and thoroughly.
- If a patient misses a dose, instruct the patient to take the next dose as scheduled.
- If a patient vomits after taking a dose, instruct the patient to take the next dose as scheduled.
2.4 Dosage Modifications for Adverse Reactions
The recommended dosage reduction for adverse reactions is to decrease the usual daily dose by 500 – 1000 mg.
Table 1 describes the dosage modifications for specific adverse reactions.
Adverse Reaction | Severity * | Dosage Modification |
---|---|---|
| ||
Adrenal Crisis and Adrenal Insufficiency [see Warnings and Precautions (5.1)] | All Grades |
|
Central Nervous System (CNS) Toxicity [see Warnings and Precautions (5.2)] | Grade 2 |
|
Grade 3 or 4 |
| |
Gastrointestinal (GI) toxicity | Grade 3 or 4 |
|
Hepatotoxicity [see Warnings and Precautions (5.4)] | Grade 3 or 4 |
|
Hematologic Toxicity [see Warnings and Precautions (5.5)] | Grade 2 |
|
Grade 3 or 4 |
| |
Other Adverse Reactions [see Adverse Reactions (6.1)] | Grade 2 |
|
Grade 3 or 4 |
|
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.